Glax­o­SmithK­line’s Hal Bar­ron poach­es Genen­tech’s top can­cer drug deal­mak­er for his new R&D team

8 years ago
People
R&D

Turn­ing cold tu­mors hot, Check­mate Phar­ma out­lines its ini­tial suc­cess sto­ry at #AACR18

8 years ago
R&D

Sang­amo probes for fresh breach­es of its dig­i­tal se­cu­ri­ty sys­tem af­ter top ex­ec’s email was hacked -- ex­pos­ing ...

8 years ago
Pharma

FDA chief Scott Got­tlieb promis­es to stream­line drug de­vel­op­ment path­way for bio­phar­ma

8 years ago
Pharma

Block­buster am­bi­tions: Am­gen/No­var­tis team lines up more promis­ing PhI­II erenum­ab da­ta for some of the tough­est ...

8 years ago
R&D

In FDA dou­ble head­er, reg­u­la­tors al­so of­fer a green light to Rigel's fos­ta­ma­tinib

8 years ago
Pharma

Ul­tragenyx wins a block­buster OK for its lead­ing rare dis­ease drug buro­sum­ab -- priced at $200,000

8 years ago
Pharma

No­var­tis pledges $100M to malar­ia ef­forts; Lil­ly, Boehringer out­lines new Jar­diance kid­ney tri­al at Ox­ford

8 years ago
News Briefing

GW Phar­ma's cannabis-based drug ap­pears poised for a ground­break­ing FDA ap­proval as in­ter­nal re­view of­fers a clear ...

8 years ago
Pharma

J&J dumps a failed PhI­II an­tibi­ot­ic pro­gram picked up in Acte­lion buy­out

8 years ago
R&D

In light of In­cyte's epaca­do­stat de­ba­cle, NewLink scraps PhI­II plans for its own IDO drug

8 years ago
R&D

Un­en­cum­bered by safe­ty con­cerns, Roche's Hem­li­bra gets break­through sta­tus for new pa­tient group

8 years ago
Pharma

Join­ing a glob­al M&A spree, Astel­las re­serves $2B for a spate of new biotech ac­qui­si­tions

8 years ago
Deals

Bris­tol-My­ers in­vites J&J in­to an al­liance of gi­ants on car­dio drug de­vel­op­ment/com­mer­cial­iza­tion pro­gram

8 years ago
R&D
Pharma

#AACR18: Roche spot­lights promis­ing sub­group re­spons­es for lung can­cer com­bo with Tecen­triq

8 years ago
R&D

Genen­tech inks $359M deal with Kine­ta; Celldex bat­tered af­ter ADC flops in PhI­Ib

8 years ago
News Briefing

Who won big at #AACR18? Mer­ck surges on Keytru­da/chemo com­bo while Bris­tol-My­ers shares tum­ble on com­par­i­son

8 years ago
R&D

#AACR: Mer­ck spot­lights piv­otal Keytru­da/chemo da­ta, hop­ing to break down skep­ti­cism to its front­line lung can­cer duo

8 years ago
R&D

#AACR: Bris­tol-My­ers tunes out sta­t­ic, broad­casts im­pres­sive re­sults for Op­di­vo/Yer­voy lung can­cer com­bo

8 years ago
R&D

End­points' Chi­na cov­er­age is get­ting deep­er. An­nounc­ing our part­ner­ship with Pharm­Cube, the lead­ing Chi­nese bio­phar­ma ...

8 years ago
Publisher's note
China

Servi­er buys Shire's on­col­o­gy unit for $2.4B in the run-up to Takeda's fi­nal buy­out of­fer — if it makes one

8 years ago
Pharma

In a stun­ning about face, the FDA is now wel­com­ing the new drug ap­pli­ca­tion from Alk­er­mes it re­ject­ed 2 weeks ago

8 years ago
Pharma

#AACR18 round 1: Mer­ck takes a di­rect swing at Bris­tol-My­ers with ad­ju­vant melanoma da­ta for Keytru­da

8 years ago
R&D

Flag­ship’s Evelo Bio­sciences pitch­es $100M IPO for a new plat­form of mon­o­clon­al mi­cro­bials

8 years ago
Financing
First page Previous page 1035103610371038103910401041 Next page Last page
A service from the Financial Times